Autopsy and Case Reports
https://autopsyandcasereports.org/article/doi/10.4322/acr.2021.309
Autopsy and Case Reports
Clinical Case Report

Palbociclib in breast cancer neoadjuvant setting

Sílvia Alexandra Cabral Duarte; Daniela Silva Pádua de Azevedo; Teresa Tomé Ribeiro Malheiro Sarmento; Marta Verónica Velho Sousa

Downloads: 0
Views: 125

Abstract

Cyclin-dependent kinase 4/6 inhibitors represent a major advance in breast cancer treatment, emerging as the standard of care of the initial treatment of hormone receptor-positive and HER2-negative metastatic breast cancer. Their activity in this subset of patients leads to interest in their use in the adjuvant and neoadjuvant settings. This case report presents a real-life case of cyclin-dependent kinase 4/6 inhibitors use in a patient initially considered to have stage IV luminal HER2-negative breast cancer with liver metastasis. The discrepancy of treatment response between the breast tumor and liver node led to a repetition of the liver biopsy, which revealed metastasis of a neuroendocrine tumor of unknown primary. The breast tumor showed a partial response, and the initial therapeutic strategy was then redefined for curative intent. While cyclin-dependent kinase 4/6 inhibitors are not yet approved for clinical practice in the neo / adjuvant treatment of hormone receptor-positive breast cancer, this case report portrays a successful example of its application in a neoadjuvant setting.

Keywords

Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Case Reports

References

1 Litière S, Isaac G, De Vries EG, et al. RECIST 1.1 for response evaluation apply not only to chemotherapy-treated patients but also to targeted cancer agents: a pooled database analysis. J Clin Oncol. 2019;37(13):1102-10. http://dx.doi.org/10.1200/JCO.18.01100. PMid:30860949.

2 Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320-7. http://dx.doi.org/10.1016/S0960-9776(03)00106-1. PMid:14659147.

3 Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020;21(2):250-60. http://dx.doi.org/10.1016/S1470-2045(19)30804-6. PMid:31859246.

4 He S, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017;9(387):eaal3986. http://dx.doi.org/10.1126/scitranslmed.aal3986. PMid:28446688.

5 Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer. Clin Cancer Res. 2017;23(15):4055-65. http://dx.doi.org/10.1158/1078-0432.CCR-16-3206. PMid:28270497.

6 Martin M, Hurvitz SA, Chan D, et al. Final results of NeoMONARCH: a phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC). In: American Association for Cancer Research, editor. Cancer research. Philadelphia: AACR; 2018.

7 Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, et al. Randomized Phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET Trial. Am J Clin Oncol. 2019;37(3):178-189

8 Curigliano G, Pardo PG, Meric-Bernstam F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016;28:191-8. http://dx.doi.org/10.1016/j.breast.2016.06.008. PMid:27336726.

9 Cottu P, D’Hondt V, Dureau S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29(12):2334-40. http://dx.doi.org/10.1093/annonc/mdy448. PMid:30307466.

10 Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33-43. http://dx.doi.org/10.1016/S1470-2045(19)30786-7. PMid:31838010.

11 Johnston SR, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of hr+, her2-, node-positive, high-risk, early breast cancer (monarche). J Clin Oncol. 2020; 38(34):3987-98.

12 Mayer E, Gnant M, DeMichele A, et al. LBA12 Pallas: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer. Ann Oncol. 2020;31:S1145. http://dx.doi.org/10.1016/j.annonc.2020.08.2240.

13 Bhattacharya K, Yang Y. A cost-effectiveness analysis of palbociclib and other aromatase inhibitors for treatment of advanced breast cancer. Value Health. 2016;19(3):PA150. http://dx.doi.org/10.1016/j.jval.2016.03.1589.

14 Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes K. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Res Treat. 2016;158(1):51-7. http://dx.doi.org/10.1007/s10549-016-3822-z. PMid:27277747.
 


Submitted date:
05/21/2021

Accepted date:
06/21/2021

Publication date:
08/20/2021

611facbaa953955c98607122 autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections